Letter by Moris et al Regarding Article, “Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes),1 there was a trend toward a lower hazard ratio in reducing the risk of the primary end point of stroke, myocardial infarction, or death in the ticagrelor group in Asian patients compared with that in the aspirin group.
First, most patients with a history of stroke or transient ischemic attack were using aspirin before inclusion. The American Heart Association guideline acknowledges a lack of evidence with respect to therapeutic options in patients who have vascular events while using aspirin, but that in these cases it is …